News

At March 31, 2009, DURECT had cash and investments of $47.0 million, compared to cash and investments of $52.7 million at December 31, 2008; these figures include restricted

Total disposable revenues were $2.8 million versus $3.0 million in the third quarter of fiscal 2008. Disposable revenues associated with the company’s core AXP AutoXpress Platform (AXP) and

The company’s case volume in the first quarter increased to 31,765 cases, up 32%, compared with the same period in 2008. The customer base of oncology and pathology

EXACT’s total revenues increased due to strategic relationship with Genzyme Corp. Exact in January entered into an intellectual property transaction with Genzyme that generated $17.2 million in cash.

Excelsior Medical, a medical device company, has received 510k clearance to sell its SwabCap luer access valve disinfection cap. According to Excelsior Medical, SwabCap is designed to assist

Juan Han, chairman and CEO of China Aoxing, said: “We are very excited to have another drug approval in year 2009. This approval further underscores China Aoxing’s long-term

Under the shared risk-reward collaboration, which will initially focus on the neuroscience area, Jubilant aims to deliver a steady stream of discovery programs to AstraZeneca. AstraZeneca will own

Izasa will target early adopters who recognize the benefits of utilizing the unique fluid balancing capabilities of RenalGuard in a cath lab setting during cardiovascular imaging procedures for

The strategic partnership will allow Lima Corporate to distribute select DJO Surgical products in several countries in Europe, while Lima Corporate will provide products for sale in the